Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Noosa News23 hours agoEnsure voices are heard – Proctor
-
Noosa News18 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business20 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
General22 hours agoMarine biologist hopes to figure out why sunfish strand along Australia’s southern coast